Increased angiogenesis and migration of dermal microvascular endothelial cells from patients with psoriasis.
Jiao LiHui HouLing ZhouJuanjuan WangJiannan LiangJunqin LiRuixia HouXuping NiuGuohua YinXinhua LiKaiming ZhangPublished in: Experimental dermatology (2021)
Psoriasis displays both increased angiogenesis and microvascular dilation in the skin, while human dermal microvascular endothelial cells (HDMECs) are involved in angiogenesis and microvascular dilation. Whether the functions of HDMECs are altered in psoriatic skin versus healthy skin remain unknown. Here, we isolated HDMECs from the skin of 10 patients with psoriasis and 10 healthy subjects and compared angiogenesis, proliferation, migration and cell metabolism between psoriatic HDMECs and normal HDMECs. We found that the morphology of primary HDMECs was comparable between psoriatic HDMECs and normal HDMECs. After passage, psoriatic HDMECs displayed larger cell size and wider intercellular space. In addition to DiI-Ac-LDL (DiI-labelled acetylated low-density lipoprotein) uptake, expression levels of CD31, vWF (von Willebrand factor) and LYVE-1 were comparable in psoriatic HDMECs versus normal HDMECs. However, psoriatic HDMECs exhibited increased tube formation (numbers of nodes and meshes, p < 0.05) and migration (numbers of migrated cells, p < 0.001) and reductions in proliferation (growth rates, p < 0.05) and energy metabolism (oxygen consumption rate and extracellular acidification rate, p < 0.05) compared with normal HDMECs. Therefore, psoriatic HDMECs display an increased angiogenesis and migration and decreased proliferation and metabolic activity, suggesting a pathogenic role of HDMECs in psoriasis.
Keyphrases
- endothelial cells
- rheumatoid arthritis
- wound healing
- disease activity
- ankylosing spondylitis
- vascular endothelial growth factor
- high glucose
- signaling pathway
- squamous cell carcinoma
- systemic lupus erythematosus
- stem cells
- bone marrow
- early stage
- radiation therapy
- low density lipoprotein
- sentinel lymph node
- neoadjuvant chemotherapy
- long non coding rna
- atopic dermatitis
- pluripotent stem cells